BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 29945142)

  • 1. An Observational Study Evaluating the Performance of LENT Score in the Selected Population of Malignant Pleural Effusion from Lung Adenocarcinoma in Singapore.
    Abisheganaden J; Verma A; Dagaonkar RS; Light RW
    Respiration; 2018; 96(4):308-313. PubMed ID: 29945142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intrapleural staphylococcal superantigen induces resolution of malignant pleural effusions and a survival benefit in non-small cell lung cancer.
    Ren S; Terman DS; Bohach G; Silvers A; Hansen C; Colt H; Sahn SA
    Chest; 2004 Nov; 126(5):1529-39. PubMed ID: 15539723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival of lung adenocarcinoma patients with malignant pleural effusion.
    Wu SG; Yu CJ; Tsai MF; Liao WY; Yang CH; Jan IS; Yang PC; Shih JY
    Eur Respir J; 2013 Jun; 41(6):1409-18. PubMed ID: 23018906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score.
    Clive AO; Kahan BC; Hooper CE; Bhatnagar R; Morley AJ; Zahan-Evans N; Bintcliffe OJ; Boshuizen RC; Fysh ET; Tobin CL; Medford AR; Harvey JE; van den Heuvel MM; Lee YC; Maskell NA
    Thorax; 2014 Dec; 69(12):1098-104. PubMed ID: 25100651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction modeling using routine clinical parameters to stratify survival in malignant pleural mesothelioma patients complicated with malignant pleural effusion.
    Zhang S; Zhang Y; Feng W; Shi Z; Shi H; Zhang Y
    Thorac Cancer; 2021 Dec; 12(24):3304-3309. PubMed ID: 34704370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can EGFR-Tyrosine Kinase Inhibitors (TKI) Alone Without Talc Pleurodesis Prevent Recurrence of Malignant Pleural Effusion (MPE) in Lung Adenocarcinoma.
    Verma A; Chopra A; Lee YW; Bharwani LD; Asmat AB; Aneez DB; Akbar FA; Lim AY; Chotirmall SH; Abisheganaden J
    Curr Drug Discov Technol; 2016; 13(2):68-76. PubMed ID: 27216707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of prognostication scores and proposal for refinement in malignant pleural effusion in Asians.
    Wong C; Wing-Cheuk Wong R; Kit-Ying So L; Yin-Chun Yam L
    Respir Med; 2021; 189():106650. PubMed ID: 34688123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can LENT Prognostic score (LDH, ECOG performance score, blood neutrophil/lymphocyte ratio, tumor type) change the clinical approach in malignant pleural effusion?
    Gayaf M; Anar C; Canbaz M; Doğan Bİ; Erbaycu AE; Güldaval F
    Tuberk Toraks; 2021 Jun; 69(2):133-143. PubMed ID: 34256503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic impact of malignant pleural effusion at presentation in patients with metastatic non-small-cell lung cancer.
    Morgensztern D; Waqar S; Subramanian J; Trinkaus K; Govindan R
    J Thorac Oncol; 2012 Oct; 7(10):1485-9. PubMed ID: 22982649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular endothelial growth factor and soluble intercellular adhesion molecule-1 in lung adenocarcinoma with malignant pleural effusion: correlations with patient survival and pleural effusion control.
    Qian Q; Zhan P; Sun WK; Zhang Y; Song Y; Yu LK
    Neoplasma; 2012; 59(4):433-9. PubMed ID: 22489699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of bevacizumab combined with chemotherapy in lung adenocarcinoma-induced malignant pleural effusion.
    Tao H; Meng Q; Li M; Shi L; Tang J; Liu Z
    Thorac Cancer; 2018 Feb; 9(2):298-304. PubMed ID: 29297985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Factors of Malignant Pleural Effusion among Palliative Care Outpatients: A Retrospective Study.
    Jeba J; Cherian RM; Thangakunam B; George R; Visalakshi J
    Indian J Palliat Care; 2018; 24(2):184-188. PubMed ID: 29736123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pleural LDH as a prognostic marker in adenocarcinoma lung with malignant pleural effusion.
    Verma A; Phua CK; Sim WY; Algoso RE; Tee KS; Lew SJ; Lim AY; Goh SK; Tai DY; Kor AC; Ho B; Abisheganaden J
    Medicine (Baltimore); 2016 Jun; 95(26):e3996. PubMed ID: 27368006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency of EGFR mutations in lung adenocarcinoma with malignant pleural effusion: Implication of cancer biological behaviour regulated by EGFR mutation.
    Zou J; Bella AE; Chen Z; Han X; Su C; Lei Y; Luo H
    J Int Med Res; 2014 Oct; 42(5):1110-7. PubMed ID: 25239875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does the LENT score risk-stratify patients with malignant pleural mesothelioma? An observational study.
    Chollet B; Guinde J; Laroumagne S; Dutau H; Astoul P
    Thorac Cancer; 2021 Jun; 12(11):1752-1756. PubMed ID: 33949775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of bevacizumab with carboplatin-pemetrexed in non-squamous non-small cell lung carcinoma patients with malignant pleural effusions: North East Japan Study Group Trial NEJ013A.
    Usui K; Sugawara S; Nishitsuji M; Fujita Y; Inoue A; Mouri A; Watanabe H; Sakai H; Kinoshita I; Ohhara Y; Maemondo M; Kagamu H; Hagiwara K; Kobayashi K;
    Lung Cancer; 2016 Sep; 99():131-6. PubMed ID: 27565928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors affecting survival in non-small cell lung carcinoma patients with malignant pleural effusions.
    Kasapoglu US; Arınç S; Gungor S; Irmak I; Guney P; Aksoy F; Bandak D; Hazar A
    Clin Respir J; 2016 Nov; 10(6):791-799. PubMed ID: 25764010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High expression of E-cadherin in pleural effusion cells predicts better prognosis in lung adenocarcinoma patients.
    Zhao C; Li X; Su C; Li J; Cheng N; Ren S; Chen X; Zhou C
    Int J Clin Exp Pathol; 2015; 8(3):3104-9. PubMed ID: 26045824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Presence of pleural effusion is associated with a poor prognosis in patients with epidermal growth factor receptor-mutated lung cancer receiving tyrosine kinase inhibitors as first-line treatment.
    Wang TF; Chu SC; Lee JJ; Yang GG; Huang WH; Chang ET; Low T; Wu YF; Kao RH; Lin CB
    Asia Pac J Clin Oncol; 2017 Aug; 13(4):304-313. PubMed ID: 28124437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion.
    Tsai TH; Wu SG; Hsieh MS; Yu CJ; Yang JC; Shih JY
    Lung Cancer; 2015 May; 88(2):208-14. PubMed ID: 25773866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.